How to Choose an Antimicrobial Resistance Detection Method

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-27

Quick Answer

• Choose polymerase chain reaction (PCR) when you need targeted detection of known resistance genes with minimal bioinformatics investment and same-day results.
• Choose whole genome sequencing (WGS) when you need comprehensive resistance mechanism discovery, outbreak tracking, and retrospective analysis with adequate computational support.
• Choose microarray when you need a middle ground of moderate throughput and cost, but verify that the panel covers the resistance determinants relevant to your organisms.

At a Glance

Understanding Genotypic Antimicrobial Resistance Detection

Antimicrobial resistance arises when bacteria acquire genetic determinants that reduce the effectiveness of antimicrobial drugs. The World Health Organization identifies antimicrobial resistance as a global public health concern that requires coordinated surveillance and stewardship efforts across human health, animal health, and environmental sectors. Genotypic detection methods identify the presence of specific resistance genes or mutations directly from bacterial isolates or clinical specimens, complementing traditional phenotypic susceptibility testing.

Phenotypic methods such as minimum inhibitory concentration testing measure the observable response of a bacterium to an antimicrobial agent. Genotypic methods instead examine the genetic basis of resistance. Each approach answers a different question. Phenotypic testing tells you whether the organism is resistant under specific test conditions. Genotypic testing tells you which resistance mechanism is present. The Clinical and Laboratory Standards Institute publishes standards for antimicrobial susceptibility testing that laboratories use to standardize their phenotypic methods and interpret results consistently.

The choice between genotypic methods depends on the laboratory's purpose. A clinical laboratory processing urgent patient samples may prioritize speed and simplicity. A reference laboratory conducting regional surveillance may prioritize breadth of detection and data portability. A research laboratory investigating novel resistance mechanisms may require the resolution of whole genome sequencing. The decision framework below addresses these distinct needs.

Core Principles of Genotypic Resistance Detection

Genotypic resistance detection relies on the principle that specific genetic sequences correlate with specific resistance phenotypes. These sequences may be acquired genes carried on plasmids or transposons, or they may be mutations in chromosomal genes that alter drug targets or regulatory pathways.

The three main genotypic approaches differ in how they interrogate the bacterial genome. PCR amplifies a targeted DNA sequence using specific primers, detecting the presence or absence of a known gene. Microarray methods use hybridization to detect the presence of many known sequences simultaneously on a solid surface. Whole genome sequencing determines the complete nucleotide sequence of the bacterial genome, allowing the identification of both known and novel resistance determinants through bioinformatics analysis.

Each method has inherent strengths and limitations. PCR is fast and inexpensive for a small number of targets but cannot detect genes outside the primer design. Microarrays can detect hundreds of targets in one run but require careful probe design and interpretation. Whole genome sequencing provides the most complete picture but requires substantial computational infrastructure and bioinformatics expertise.

The choice of method also depends on the specimen type. Direct testing of clinical specimens may require methods that tolerate mixed bacterial populations and low target concentrations. Testing of pure isolates allows for more flexible method selection. Laboratories must also consider the biosafety implications of their workflow, and the CDC and NIH provide guidance on risk assessment and containment practices for handling potentially hazardous microorganisms.

PCR for Targeted Resistance Gene Detection

Polymerase chain reaction is the most widely used genotypic method for antimicrobial resistance detection. The method amplifies a specific DNA sequence using short primers that flank the target region. The presence of an amplification product indicates the presence of the target gene in the sample.

Technical considerations for PCR

PCR requires a thermal cycler, DNA polymerase, primers, nucleotides, and a detection system. The detection system may be gel-based, using agarose gel electrophoresis to visualize amplified products, or real-time, using fluorescent probes to monitor amplification as it occurs. Real-time PCR offers the advantage of quantitative measurement and does not require post-amplification handling, which reduces the risk of contamination.

Primer design is the most critical step in PCR development. Primers must be specific to the target gene and must not cross-react with other bacterial sequences. Laboratories can use published primer sets or design their own using sequence databases. The American Society for Microbiology provides educational resources and professional guidance for laboratory practice, including molecular diagnostics.

Multiplex PCR

Multiplex PCR allows the simultaneous detection of multiple target genes in a single reaction. This approach is useful when a laboratory needs to screen for several resistance genes that are common in a particular organism or clinical context. For example, a laboratory may use a multiplex PCR panel to detect the most common carbapenemase genes in Gram-negative bacteria.

The limitation of multiplex PCR is the complexity of primer design. Each primer pair must work under the same reaction conditions, and the amplified products must be distinguishable from each other. The number of targets in a single multiplex reaction is typically limited to five to ten genes.

PCR limitations

PCR can only detect genes that are known and included in the primer set. Novel resistance genes will not be detected. PCR also cannot determine whether a detected gene is expressed and functional. A gene may be present but not contribute to the observed phenotype due to regulatory mutations or gene silencing.

PCR is also susceptible to false-negative results if the primer binding sites contain mutations. Sequence variation in the target gene can prevent primer binding and lead to a negative result despite the presence of the gene. Laboratories should validate their PCR assays against a panel of known positive and negative control strains. The American Type Culture Collection provides authenticated biological materials that can be used for quality control and assay validation.

Microarray for Broad Resistance Gene Detection

Microarray technology allows the simultaneous detection of hundreds or thousands of target sequences in a single experiment. The method uses a solid surface, typically a glass slide or a bead-based system, with immobilized probes that hybridize to complementary DNA sequences in the sample.

How microarrays work

The sample DNA is labeled with a fluorescent dye and hybridized to the array. The presence of a target sequence is detected by the fluorescence signal at the corresponding probe location. The intensity of the signal can provide semi-quantitative information about the amount of target DNA in the sample.

Microarrays are well suited for surveillance applications where a laboratory needs to screen for a broad panel of resistance genes across many samples. The method is more efficient than running many individual PCR reactions for each gene.

Microarray design considerations

The design of a microarray panel requires knowledge of the resistance genes that are relevant to the target population. The panel must be updated as new resistance genes are discovered. The specificity of the probes must be validated to avoid cross-hybridization with closely related sequences.

Microarray data analysis requires specialized software to normalize the fluorescence signals and call the presence or absence of each target. The analysis is more complex than PCR interpretation but less demanding than whole genome sequencing bioinformatics.

Microarray limitations

Microarrays share the fundamental limitation of PCR in that they can only detect known sequences. The panel is fixed at the time of array design, and new resistance genes will not be detected until the panel is updated.

The cost of microarrays is higher than PCR for a small number of targets but lower than whole genome sequencing for a large number of targets. The turnaround time is typically one to two days, which is longer than PCR but shorter than whole genome sequencing.

Microarrays also require careful quality control to ensure consistent hybridization across runs. The Clinical and Laboratory Standards Institute provides standards for antimicrobial susceptibility testing that laboratories can use to establish quality control procedures for their genotypic methods.

Whole Genome Sequencing for Comprehensive Resistance Profiling

Whole genome sequencing provides the most complete characterization of the bacterial genome. The method determines the complete nucleotide sequence of the organism, allowing the identification of all resistance genes and mutations present.

Sequencing platforms

Several sequencing platforms are available for whole genome sequencing. Short-read platforms produce many short sequences that are assembled into a draft genome. Long-read platforms produce longer sequences that can resolve repetitive regions and provide a more complete assembly. The choice of platform depends on the laboratory budget, the intended use of the data, and the available bioinformatics infrastructure.

Bioinformatics analysis

The bioinformatics analysis is the most significant challenge for whole genome sequencing. The raw sequencing data must be processed through a series of steps, including quality control, assembly, and annotation. The resistance genes are then identified by comparing the assembled genome against a database of known resistance genes.

The bioinformatics requirement is a major consideration for laboratories considering WGS. The laboratory must have access to computational resources and personnel with bioinformatics expertise. The analysis can be performed using local servers or cloud-based platforms, but both require a level of technical skill.

WGS advantages

WGS provides the most complete picture of the resistance profile. It can detect known resistance genes, novel resistance genes, and mutations that confer resistance. The data can also be used for other purposes, such as typing, outbreak investigation, and phylogenetic analysis.

WGS data are also permanent. The sequence data can be reanalyzed as new resistance genes are discovered, without the need to re-sequence the sample. This is a significant advantage over PCR and microarrays, which require a new experiment for each new target.

WGS limitations

The cost of WGS has decreased substantially in recent years, but the initial investment in sequencing equipment and bioinformatics infrastructure remains significant. The turnaround time is longer than PCR, typically two to five days from sample to final result.

WGS also requires a pure culture of the organism. The method cannot be applied directly to mixed clinical specimens without a culture step. This adds time to the workflow and requires the organism to be culturable.

The interpretation of WGS data requires careful consideration. The presence of a resistance gene does not always correlate with the resistance phenotype. The gene may be non-functional, or the expression may be regulated by other factors. The correlation between genotype and phenotype must be established for each organism and each drug.

Decision Framework for Method Selection

The selection of a genotypic method requires a systematic evaluation of laboratory needs, resources, and constraints. The following framework provides a structured approach to the decision.

Step 1: Define the laboratory objective

The first step is to define the primary objective of the resistance detection. The objective may be clinical diagnosis, surveillance, outbreak investigation, or research. Each objective has different requirements for turnaround time, throughput, and resolution.

Clinical diagnosis requires a rapid turnaround time and high sensitivity for the most clinically relevant genes. Surveillance requires high throughput and the ability to detect a broad range of genes. Outbreak investigation requires the resolution to distinguish between closely related strains. Research may require the ability to detect novel genes and mutations.

Step 2: Assess the sample volume and throughput

The expected sample volume is a major determinant of the method choice. A laboratory processing a small number of samples per week may find PCR to be the most cost-effective option. A laboratory processing hundreds of samples per week may need the throughput of microarrays or WGS.

The throughput of each method is different. PCR can process a moderate number of samples per run, but the number of targets per sample is limited. Microarrays can process many samples with many targets per sample. WGS can process many samples, but the bioinformatics analysis is the bottleneck.

Step 3: Evaluate the bioinformatics infrastructure

The bioinformatics infrastructure is a critical consideration for WGS and, to a lesser extent, for microarrays. The laboratory must have access to computers with sufficient processing power, storage capacity, and the appropriate software. The laboratory must also have personnel with the training to perform the analysis.

PCR requires minimal bioinformatics. The interpretation of PCR results is straightforward and can be performed by laboratory personnel with basic training. Microarrays require some bioinformatics for signal interpretation. WGS requires the most bioinformatics expertise.

Step 4: Calculate the total cost

The total cost of each method includes the equipment cost, the consumable cost per sample, the personnel cost, and the infrastructure cost. The equipment cost is highest for WGS and lowest for PCR. The consumable cost per sample is highest for WGS and lowest for PCR for a small number of targets. The personnel cost depends on the level of training required for the method.

The cost per sample decreases as the number of samples increases. A laboratory with a high sample volume may find that the cost per sample for WGS is competitive with the cost per sample for PCR when the number of targets is large.

Step 5: Consider the regulatory and quality requirements

The laboratory must consider the regulatory and quality requirements for the method. The Clinical and Laboratory Standards Institute provides standards for antimicrobial susceptibility testing that may apply to genotypic methods. The laboratory must also follow the biosafety requirements for handling the bacterial isolates.

The laboratory must validate the method before it is used for clinical or surveillance purposes. The validation must include the accuracy, precision, and reproducibility of the method. The laboratory must also establish quality control procedures to ensure the ongoing performance of the method.

Practical Implementation Steps

The implementation of a genotypic method requires a systematic approach. The following steps provide a framework for the implementation.

Step 1: Conduct a needs assessment

The first step is to conduct a needs assessment to define the laboratory requirements. The assessment should include the sample volume, the target organisms, the target resistance genes, the turnaround time, and the budget. The assessment should also include the available infrastructure, including the equipment, the personnel, and the computational resources.

Step 2: Select the method

The method selection should be based on the needs assessment. The decision framework in the previous section provides a structured approach to the selection. The laboratory should also consider the availability of the method in the market and the support from the manufacturer.

Step 3: Acquire the equipment and supplies

The equipment and supplies should be acquired from a reputable supplier. The laboratory should verify that the equipment is properly installed and calibrated. The supplies should be stored according to the manufacturer recommendations.

Step 4: Train the personnel

The personnel must be trained in the operation of the equipment and the performance of the method. The training should include the sample preparation, the assay performance, the data analysis, and the troubleshooting. The training should be documented and the personnel should be assessed for competency.

Step 5: Validate the method

The method must be validated before it is used for clinical or surveillance purposes. The validation should include the accuracy, the precision, the reproducibility, and the limit of detection. The validation should use authenticated reference strains from a culture collection such as the American Type Culture Collection.

Step 6: Establish quality control procedures

The quality control procedures should be established to ensure the ongoing performance of the method. The procedures should include the use of positive and negative controls, the monitoring of the equipment performance, and the review of the results. The quality control data should be recorded and reviewed on a regular basis.

Step 7: Implement the method

The method should be implemented in the laboratory workflow. The implementation should include the standard operating procedures, the result reporting, and the data management. The implementation should be monitored to identify any issues and to make the necessary adjustments.

Records and Measurements

The laboratory should maintain records of the genotypic testing. The records should include the sample identification, the date of the test, the method used, the results, and the interpretation. The records should be maintained in a format that allows for the review and the audit.

The laboratory should also maintain records of the quality control data. The quality control data should include the results of the positive and negative controls, the equipment performance, and the personnel competency. The quality control data should be reviewed on a regular basis to identify any trends or issues.

The laboratory should also maintain records of the validation data. The validation data should include the accuracy, the precision, the reproducibility, and the limit of detection. The validation data should be reviewed when there is a change in the method or the equipment.

Common Failure Patterns

The following are common failure patterns in genotypic resistance testing.

Contamination

Contamination is the most common cause of false-positive results in PCR. The contamination can come from the previous amplification products, the laboratory environment, or the reagents. The laboratory should use separate areas for the preparation of the reagents, the handling of the samples, and the amplification. The laboratory should also use appropriate controls to detect contamination.

Primer or probe failure

The primer or probe failure can cause false-negative results. The primer or probe may not bind to the target sequence due to the sequence variation. The laboratory should validate the primers and probes against a panel of known positive and negative controls. The laboratory should also monitor the performance of the primers and probes on a regular basis.

Bioinformatics errors

The bioinformatics errors can cause the misinterpretation of the results. The errors may be due to the quality of the sequencing data, the assembly of the genome, or the identification of the resistance genes. The laboratory should use a validated bioinformatics pipeline and should review the results by a trained bioinformatician.

Interpretation errors

The interpretation errors can occur when the presence of a resistance gene is not correlated with the phenotypic resistance. The laboratory should be aware of the limitations of the genotypic methods and should interpret the results in the context of the phenotypic data.

Safety and Regulatory Context

The laboratory must follow the biosafety requirements for the handling of the microorganisms. The CDC and NIH provide guidance for the risk assessment and the containment of the microorganisms in the laboratory. The laboratory should conduct a risk assessment for the organisms that are handled and should implement the appropriate containment measures.

The laboratory must also follow the regulatory requirements for the use of the genotypic methods. The Clinical and Laboratory Standards Institute provides standards for the antimicrobial susceptibility testing. The laboratory should follow the standards that are applicable to the method.

The laboratory should also follow the requirements for the reporting of the results. The results should be reported in a format that is clear and that is useful for the clinical or the surveillance purposes. The results should be interpreted in the context of the phenotypic data and the clinical situation.

Professional Escalation Criteria

The laboratory should have a process for the escalation of the results that are unusual or that require the additional investigation. The escalation criteria should include the following:

• The detection of a resistance gene that is not commonly seen in the laboratory.
• The detection of a resistance gene that is not consistent with the phenotypic resistance.
• The detection of a novel resistance gene that has not been previously described.
• The detection of a resistance gene in an organism that is not commonly associated with the gene.

The escalation should include the notification of the laboratory director, the review of the results, and the additional testing if necessary. The escalation should be documented in the laboratory records.

Building a Cost Model for Genotypic Method Selection

The decision to implement PCR, microarray, or whole genome sequencing for antimicrobial resistance detection often fails not on technical merit but on incomplete cost accounting. Laboratory directors frequently compare only the consumable cost per sample and overlook the full cost of ownership that includes equipment depreciation, personnel time, quality control materials, data storage, and the hidden cost of repeat testing when a method does not fit the workflow. A structured cost model provides a defensible basis for method selection and for budget justification to institutional leadership.

Fixed Costs versus Variable Costs

The first step in building a cost model is to separate fixed costs from variable costs. Fixed costs are incurred regardless of the number of samples processed. Variable costs change with the sample volume. This distinction matters because a method with high fixed costs but low variable costs may become economical at high throughput, while a method with low fixed costs but high variable costs may be preferable for a low-volume laboratory.

Fixed costs include the purchase price of the thermal cycler, the microarray scanner, or the sequencing instrument. These costs also include installation, initial training, and the service contract that covers preventive maintenance and repairs. For whole genome sequencing, the fixed cost category must include the server or cloud computing allocation for bioinformatics analysis. The American Society for Microbiology provides professional guidance on laboratory practice that emphasizes the importance of budgeting for the full infrastructure required by a method, beyond the instrument itself.

Variable costs include reagents, consumables, and disposables that are consumed for each sample. For PCR, these are the master mix, primers, probes, and plasticware. For microarrays, these are the arrays, labeling reagents, and hybridization buffers. For whole genome sequencing, these are the library preparation kits, sequencing reagents, and flow cells. Variable costs also include the quality control materials that must be run alongside each batch of samples.

Personnel time is a cost category that is often underestimated. The hands-on time required for each method differs substantially. PCR requires relatively short hands-on time for DNA extraction and reaction setup. Microarrays require additional time for hybridization and washing steps. Whole genome sequencing requires significant hands-on time for library preparation and also requires bioinformatics personnel time for data analysis. The cost of personnel time should be calculated using the fully loaded salary that includes benefits and overhead.

Calculating Cost per Sample

The cost per sample is calculated by dividing the total annual cost by the annual sample volume. The total annual cost includes the annualized fixed costs plus the total variable costs. The annualized fixed cost is calculated by dividing the total fixed cost by the useful life of the equipment, typically five to seven years for laboratory instruments.

A practical formula for the cost per sample is:

Cost per sample equals annualized fixed cost divided by annual sample volume plus variable cost per sample plus personnel cost per sample.

This formula reveals the economy of scale that is inherent in each method. A PCR instrument with a fixed cost of 25000 currency units and a useful life of five years has an annualized fixed cost of 5000 currency units. At a volume of 100 samples per year, the fixed cost contribution is 50 currency units per sample. At a volume of 1000 samples per year, the fixed cost contribution drops to 5 currency units per sample.

The same logic applies to whole genome sequencing, where the fixed cost is much higher. A sequencing instrument with a fixed cost of 150000 currency units and a useful life of five years has an annualized fixed cost of 30000 currency units. At a volume of 500 samples per year, the fixed cost contribution is 60 currency units per sample. At a volume of 2000 samples per year, the fixed cost contribution drops to 15 currency units per sample.

The cost per sample for whole genome sequencing also depends on the multiplexing level, which is the number of samples that can be sequenced simultaneously on a single flow cell. Higher multiplexing reduces the consumable cost per sample but increases the bioinformatics burden because each sample still requires individual analysis.

Building the Cost Model Spreadsheet

A cost model spreadsheet should include the following line items for each method under consideration:

Equipment purchase price, equipment useful life, annual service contract cost, installation and initial training cost, annualized equipment cost, reagent cost per sample, consumable cost per sample, quality control material cost per sample, hands-on personnel time per sample, bioinformatics personnel time per sample, fully loaded hourly personnel rate, personnel cost per sample, data storage cost per sample, and annual sample volume.

The spreadsheet should calculate the total annual cost and the cost per sample for each method at the expected annual sample volume. The spreadsheet should also include a sensitivity analysis that shows how the cost per sample changes at different sample volumes. This sensitivity analysis is important because the actual sample volume may differ from the initial estimate.

The cost model should also include the cost of method validation. Validation requires authenticated reference strains from a culture collection such as the American Type Culture Collection. The validation cost includes the purchase of the reference strains, the reagents used for the validation experiments, and the personnel time for the validation study. The validation cost is a one-time cost that should be amortized over the expected life of the method.

Comparing Methods at Different Sample Volumes

The cost model becomes most useful when it is used to compare methods at different sample volumes. A laboratory processing 50 samples per month may find that PCR has the lowest cost per sample because the fixed cost of the PCR instrument is low and the variable cost per sample is moderate. A laboratory processing 500 samples per month may find that microarray has the lowest cost per sample because the fixed cost is amortized over a larger volume and the variable cost per sample is lower than PCR when many targets are tested per sample.

A laboratory processing 2000 samples per month may find that whole genome sequencing has a competitive cost per sample, especially when the laboratory needs to test for a large number of resistance genes. The cost per target for whole genome sequencing decreases as the number of targets increases because the sequencing cost is independent of the number of genes analyzed. In contrast, the cost per target for PCR increases with the number of targets because each additional target requires additional primers and probes.

The cost model should also account for the cost of repeat testing. If a method produces results that are ambiguous or that require confirmation by a second method, the cost of the repeat testing must be included in the total cost. PCR results that are positive for a resistance gene may require phenotypic confirmation. Whole genome sequencing results that identify a novel resistance gene may require additional characterization. The cost model should include an estimate of the repeat testing rate for each method.

Total Cost of Ownership for Bioinformatics

The bioinformatics cost is a significant component of the total cost of ownership for whole genome sequencing and, to a lesser extent, for microarrays. The bioinformatics cost includes the purchase or rental of the computational infrastructure, the software licenses, and the personnel time for data analysis.

For whole genome sequencing, the bioinformatics cost can be calculated as the cost of the server or cloud computing allocation plus the cost of the bioinformatics personnel time. The server cost includes the purchase price, the electricity, the cooling, and the maintenance. The cloud computing cost is based on the amount of computational time and storage used for each sample.

The bioinformatics personnel time depends on the level of automation in the analysis pipeline. A fully automated pipeline that runs without manual intervention requires less personnel time than a semi-automated pipeline that requires manual review of each step. The laboratory should estimate the bioinformatics personnel time per sample based on the complexity of the analysis and the experience of the personnel.

The data storage cost is often overlooked. Whole genome sequencing generates a large amount of raw data that must be stored for a period of time. The storage cost depends on the amount of data generated per sample and the retention period required by the laboratory or by regulatory requirements. The cost model should include the data storage cost per sample.

Using the Cost Model for Decision Making

The cost model provides a structured basis for the method selection decision. The laboratory director should run the cost model for each method at the expected sample volume and compare the cost per sample. The director should also run the cost model at different sample volumes to understand how the cost per sample changes with the volume.

The cost model should be used in combination with the technical considerations described in the decision framework. A method may have the lowest cost per sample but may not meet the turnaround time requirement or may not have the resolution needed for the laboratory objective. The cost model provides the financial data that informs the decision, but the decision must also consider the technical and operational factors.

The cost model should be reviewed and updated on a regular basis. The reagent costs, the personnel costs, and the equipment costs may change over time. The sample volume may also change. The laboratory should update the cost model at least annually to ensure that the method selection remains appropriate.

Documenting the Cost Model

The cost model should be documented in a format that can be reviewed by the laboratory director and by institutional leadership. The documentation should include the assumptions used in the model, the sources of the cost data, and the date of the last update. The documentation should also include the sensitivity analysis that shows how the cost per sample changes at different sample volumes.

The documentation should be maintained as part of the laboratory quality management system. The Clinical and Laboratory Standards Institute provides standards for antimicrobial susceptibility testing that emphasize the importance of documentation and quality management in the laboratory. The cost model documentation should be reviewed when there is a significant change in the cost of reagents, equipment, or personnel.

Common Errors in Cost Modeling

Several common errors can undermine the accuracy of a cost model. The first error is omitting the personnel cost. The personnel cost is often the largest component of the total cost per sample, especially for methods that require significant hands-on time or bioinformatics expertise. The cost model should include the fully loaded personnel cost for all personnel involved in the testing process.

The second error is underestimating the quality control cost. Quality control materials are required for each batch of samples, and the cost of these materials can be significant. The cost model should include the quality control material cost per batch and should allocate this cost across the samples in the batch.

The third error is ignoring the cost of repeat testing. If a method produces ambiguous results that require confirmation, the cost of the repeat testing must be included in the total cost. The cost model should include an estimate of the repeat testing rate for each method.

The fourth error is using the list price instead of the negotiated price for reagents and consumables. Laboratories often negotiate discounts with suppliers based on volume or contract terms. The cost model should use the actual price paid by the laboratory, not the list price.

The fifth error is failing to account for the cost of equipment downtime. If the equipment fails and samples must be sent to a reference laboratory, the cost of the referral testing must be included in the total cost. The cost model should include an estimate of the equipment downtime rate and the cost of the referral testing.

Integrating the Cost Model with the Decision Framework

The cost model should be integrated with the decision framework described in the previous section. The decision framework defines the laboratory objective, assesses the sample volume and throughput, evaluates the bioinformatics infrastructure, and considers the regulatory and quality requirements. The cost model provides the financial data that completes the decision.

The laboratory director should use the cost model to compare the total cost of ownership for each method at the expected sample volume. The director should also use the cost model to identify the break-even point where one method becomes more cost-effective than another. The break-even point is the sample volume at which the total cost per sample for two methods is equal.

The break-even analysis is particularly useful for comparing PCR and whole genome sequencing. At low sample volumes, PCR has a lower cost per sample because the fixed cost is lower. At high sample volumes, whole genome sequencing may have a lower cost per sample because the variable cost per sample decreases with multiplexing and the cost per target is lower. The break-even analysis identifies the sample volume at which the laboratory should switch from PCR to whole genome sequencing.

Presenting the Cost Model to Stakeholders

The cost model provides the evidence needed to present the method selection decision to institutional leadership. The presentation should include the cost per sample for each method at the expected sample volume, the sensitivity analysis that shows how the cost per sample changes at different sample volumes, and the break-even analysis that identifies the sample volume at which one method becomes more cost-effective than another.

The presentation should also include the non-financial factors that inform the decision, such as the turnaround time, the throughput, the bioinformatics requirement, and the clinical utility. The World Health Organization emphasizes the importance of antimicrobial resistance surveillance and stewardship as a global public health priority. The presentation should connect the method selection decision to the laboratory role in supporting antimicrobial resistance surveillance and stewardship.

The presentation should be clear and should use tables and charts to communicate the cost data. The presentation should also include the assumptions used in the cost model and the sources of the cost data. The presentation should be reviewed by the laboratory director before it is presented to institutional leadership.

Updating the Cost Model

The cost model should be updated on a regular basis to reflect changes in the cost of reagents, equipment, personnel, and data storage. The cost model should also be updated when there is a change in the sample volume or when a new method becomes available.

The laboratory should establish a schedule for updating the cost model. The cost model should be reviewed at least annually and should be updated when there is a significant change in any of the cost inputs. The updated cost model should be documented and the changes should be reviewed by the laboratory director.

The cost model is a living document that should be maintained as part of the laboratory quality management system. The cost model provides the financial evidence that supports the method selection decision and that justifies the budget request to institutional leadership. A well-maintained cost model ensures that the laboratory method selection remains appropriate as the sample volume, the cost structure, and the available methods change over time.

Frequently Asked Questions

What is the difference between genotypic and phenotypic antimicrobial resistance testing?

Genotypic testing detects the genetic determinants of resistance, such as resistance genes or mutations. Phenotypic testing measures the observable response of the bacterium to an antimicrobial drug, such as the minimum inhibitory concentration. Genotypic testing identifies the mechanism of resistance, while phenotypic testing identifies the level of resistance.

Which genotypic method is the most cost-effective for a small laboratory?

PCR is the most cost-effective method for a small laboratory with a low sample volume and a limited number of target genes. The equipment cost is lower than the equipment cost for microarrays or WGS, and the consumable cost per sample is lower for a small number of targets.

Can whole genome sequencing detect all antimicrobial resistance genes?

Whole genome sequencing can detect all resistance genes that are present in the genome, including novel genes that are not in the databases. The detection of the genes depends on the quality of the sequencing data and the completeness of the resistance gene database. The presence of a gene does not always mean that the gene is functional.

How long does it take to get results from each genotypic method?

PCR results can be obtained in a few hours. Microarray results can be obtained in one to two days. Whole genome sequencing results can be obtained in two to five days, depending on the sequencing platform and the bioinformatics analysis.

What bioinformatics skills are needed for whole genome sequencing?

Whole genome sequencing requires skills in the quality control of the sequencing data, the assembly of the genome, and the identification of the resistance genes. The laboratory must have access to the computational resources and the software for the analysis. The bioinformatics analysis can be performed by a trained bioinformatician or by a laboratory scientist with the appropriate training.

Can genotypic methods replace phenotypic susceptibility testing?

Genotypic methods cannot replace phenotypic susceptibility testing. Genotypic methods detect the presence of resistance genes, but they cannot determine the level of resistance. Phenotypic testing is required to determine the minimum inhibitory concentration and to guide the clinical treatment. The two methods are complementary and are used together in the laboratory.

What quality control measures are needed for genotypic testing?

The quality control measures include the use of positive and negative controls, the validation of the method, the monitoring of the equipment performance, and the review of the results. The quality control data should be recorded and reviewed on a regular basis. The laboratory should also participate in the external quality assessment programs.

How should a laboratory validate a new genotypic method?

The validation should include the accuracy, the precision, the reproducibility, and the limit of detection. The validation should use a panel of known positive and negative control strains. The validation should be documented and the results should be reviewed by the laboratory director.

Using the Evidence

Related Bacteriology Guides

• Biological Foundation Models for Antimicrobial Peptide Discovery in Veterinary Pathogens
• Aeromonas hydrophila in Aquaculture: Virulence Factors and Antimicrobial Resistance
• Swine Bacterial Diseases: Colibacillosis, UTI, and Antimicrobial Resistance
• Avian Colibacillosis: Pathogenesis, Diagnosis, and Antimicrobial Resistance Patterns in Poultry
• Salmonellosis in Poultry: Serovar Surveillance, Antimicrobial Resistance, and Egg Safety

References and Further Reading

• Biosafety in Microbiological and Biomedical Laboratories. CDC and NIH.
• Microbiology Resources. American Society for Microbiology.
• Antimicrobial Resistance. World Health Organization.
• Bacteriological Analytical Manual. U.S. Food and Drug Administration.
• Antimicrobial Susceptibility Testing. Clinical and Laboratory Standards Institute.
• Culture Collections. American Type Culture Collection.
• NCBI Pathogen Detection. National Center for Biotechnology Information.
• Laboratory detection of carbapenemases among Gram-negative organisms.. Clinical microbiology reviews, 2024.
• Molecular detection of Helicobacter pylori and its genotypic antimicrobial resistance patterns in dyspeptic Mozambican patients.. Helicobacter, 2023.
• Molecular antimicrobial susceptibility testing in sepsis.. Future microbiology, 2024.
• Artificial Intelligence for Antimicrobial Resistance Detection and Prediction in Klebsiella pneumoniae: A Systematic Review of Clinical Microbiology Applications.. Infection and drug resistance, 2026.

This article is educational and does not replace validated laboratory procedures, clinical diagnosis, institutional biosafety review, or public-health guidance.